Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

781 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19: Discovery, diagnostics and drug development.
Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. Asselah T, et al. Among authors: lau g. J Hepatol. 2021 Jan;74(1):168-184. doi: 10.1016/j.jhep.2020.09.031. Epub 2020 Oct 8. J Hepatol. 2021. PMID: 33038433 Free PMC article. Review.
Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.
Marcellin P, Wursthorn K, Wedemeyer H, Chuang WL, Lau G, Avila C, Peng CY, Gane E, Lim SG, Fainboim H, Foster GR, Safadi R, Rizzetto M, Manns M, Bao W, Trylesinski A, Naoumov N. Marcellin P, et al. Among authors: lau g. J Hepatol. 2015 Jan;62(1):41-7. doi: 10.1016/j.jhep.2014.08.021. Epub 2014 Aug 23. J Hepatol. 2015. PMID: 25152207 Clinical Trial.
Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents.
Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, Wu V, Wong A, Wang Y, Zhang X, Lu L, Wong C, Tsang S, Zhang Z, Sun J, Hou J, Chen G, Lau G. Wang C, et al. Among authors: lau g. Clin Gastroenterol Hepatol. 2017 Jan;15(1):132-136. doi: 10.1016/j.cgh.2016.06.023. Epub 2016 Jul 5. Clin Gastroenterol Hepatol. 2017. PMID: 27392759
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Lau G, Benhamou Y, Chen G, Li J, Shao Q, Ji D, Li F, Li B, Liu J, Hou J, Sun J, Wang C, Chen J, Wu V, Wong A, Wong CL, Tsang ST, Wang Y, Bassit L, Tao S, Jiang Y, Hsiao HM, Ke R, Perelson AS, Schinazi RF. Lau G, et al. Lancet Gastroenterol Hepatol. 2016 Oct;1(2):97-104. doi: 10.1016/S2468-1253(16)30015-2. Epub 2016 Jul 25. Lancet Gastroenterol Hepatol. 2016. PMID: 27917405 Free PMC article. Clinical Trial.
Shortening the duration of therapy for chronic hepatitis C infection.
Emmanuel B, Wilson EM, O'Brien TR, Kottilil S, Lau G. Emmanuel B, et al. Among authors: lau g. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):832-836. doi: 10.1016/S2468-1253(17)30053-5. Epub 2017 Aug 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28802815 Free PMC article. Review.
781 results